Furthermore, the alleviation of cardiac hypertrophy by NAD+ elevation in CD38 knockout mice is similar to the protection reported in the mutation of another NAD+‐consuming enzyme PARP1 48, 49. This evidence concerns the gene PARP1 and cardiac hypertrophy.